Coenzyme-A Inc. (PPII) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Coenzyme-A Inc. (PPII) trades at $0.0002. Coenzyme-A Inc. formulates and manufactures nutraceutical supplements, skin, and hair care products, operating both domestically and internationally. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for PPII: PPII does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PPII against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on PPII.
How is this calculated? →Coenzyme-A Inc. (PPII) Healthcare & Pipeline Overview
Coenzyme-A Inc. is a nutraceutical and personal care product manufacturer, offering a range of supplements, skin, and hair care solutions. Founded in 1998, the company targets diverse consumer needs with specialized formulas for energy, beauty, and wellness, operating in the competitive specialty and generic drug market.
What Is the Investment Thesis for PPII?
Coenzyme-A Inc. presents a focused approach to the nutraceutical and personal care market, with a diverse product range and international presence. The company's gross margin of 66.1% indicates efficient operations. Key value drivers include expanding its product lines and penetrating new geographic markets. Growth catalysts involve capitalizing on the increasing consumer interest in health and wellness products. Potential risks include competition from larger players and the challenges of operating in the OTC market. Investors may want to evaluate the company's OTC status and associated risks.
Based on FMP financials and quantitative analysis
PPII Key Highlights
Coenzyme-A Inc. operates in the nutraceutical and personal care market, offering a range of supplements and skin/hair care products.
- The company's gross margin stands at 66.1%, reflecting its operational efficiency.
- Coenzyme-A Inc. was founded in 1998 and is based in Lynnwood, Washington.
- The company's beta is 1.59, indicating higher volatility compared to the market average.
- Coenzyme-A Inc. does not offer a dividend, reinvesting earnings for growth.
Who Are PPII's Competitors?
PPII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PPII's Key Strengths?
Diverse product portfolio in nutraceuticals and personal care.
- Established presence in the United States and international markets.
- High gross margin of 66.1%.
- Specialized product lines targeting specific health needs.
What Are PPII's Weaknesses?
OTC market listing increases volatility and risk.
- Limited brand recognition compared to larger competitors.
- Dependence on specific distribution channels.
- Potential challenges in navigating regulatory requirements.
What Could Drive PPII Stock Higher?
Potential new product launches in the nutraceutical or personal care space.
- Expansion into new geographic markets, particularly in Asia-Pacific.
- Strategic partnerships or acquisitions to expand product portfolio.
- Increased marketing and promotional activities to drive brand awareness.
What Are the Key Risks for PPII?
Intense competition from established players in the nutraceutical market.
- Changing consumer preferences and trends.
- Regulatory changes and compliance requirements.
- Economic downturns affecting consumer spending on discretionary products.
- Risks associated with operating in the OTC market, including limited liquidity and disclosure.
What Are the Growth Opportunities for PPII?
- Expansion into Emerging Markets: Coenzyme-A Inc. can pursue growth by expanding its presence in emerging markets. The nutraceuticals market in regions like Asia-Pacific and Latin America is experiencing rapid growth due to rising disposable incomes and increasing health awareness. By tailoring its product offerings to local preferences and establishing strategic partnerships, Coenzyme-A Inc. can tap into these high-growth markets. This expansion could contribute significantly to revenue growth within the next 3-5 years.
- Product Innovation and Development: Coenzyme-A Inc. can drive growth through continuous product innovation and development. By investing in research and development, the company can introduce new and improved formulations, addressing emerging health needs and consumer preferences. This includes developing products with clinically proven benefits and incorporating innovative ingredients. Successful product launches can attract new customers and increase market share, with potential revenue impact within 2-3 years.
- Strategic Partnerships and Acquisitions: Coenzyme-A Inc. can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other companies in the nutraceutical and personal care space can provide access to new technologies, distribution channels, and customer segments. Acquiring complementary businesses can further diversify the company's offerings and strengthen its competitive position. These initiatives can lead to increased revenue and market share within 3-5 years.
- Enhancing Online Presence and E-commerce Capabilities: Coenzyme-A Inc. can enhance its online presence and e-commerce capabilities to reach a wider customer base and drive sales. By investing in a user-friendly website, implementing effective digital marketing strategies, and offering convenient online ordering and delivery options, the company can attract and retain online customers. This includes leveraging social media platforms and influencer marketing to promote its products and engage with consumers. Improved online presence can lead to increased sales and brand awareness within 1-2 years.
- Focusing on Personalized Nutrition: Coenzyme-A Inc. can capitalize on the growing trend of personalized nutrition by offering customized product recommendations and solutions. By leveraging data analytics and consumer insights, the company can develop personalized supplement plans tailored to individual health needs and preferences. This includes offering online assessments, providing expert consultations, and delivering customized product bundles. Personalized nutrition can enhance customer engagement and loyalty, driving revenue growth within 2-3 years.
What Are PPII's Competitive Advantages?
- Proprietary Formulations: Coenzyme-A Inc. may have unique formulations that differentiate its products from competitors.
- Brand Recognition: Established brand recognition in specific product categories can create customer loyalty.
- Distribution Network: A well-established distribution network can provide a competitive advantage.
- Specialized Product Lines: Focus on specific customer segments (e.g., sports nutrition, women's health) can create a niche advantage.
What Does PPII Do?
Coenzyme-A Inc., established in 1998 and headquartered in Lynnwood, Washington, formulates and manufactures a diverse range of nutraceutical supplements, as well as skin and hair care products. The company operates both in the United States and internationally, catering to a broad consumer base with varied health and wellness needs. Its product portfolio includes energy drinks, skin rejuvenating serums, fat management solutions, skin treatments, and products designed to support fatty acid and cholesterol metabolism. Coenzyme-A Inc. also offers nutritional formulas targeting specific health areas, such as bone, joint, ligament, cartilage, and connective tissue support. Furthermore, the company provides specialized product lines tailored to different demographics, including sports-specific formulas, women's health products, and men's health supplements. Its offerings extend to wellness, energy, and body sculpting products, reflecting a comprehensive approach to health and personal care. The company aims to address a wide array of consumer demands within the nutraceutical and personal care markets.
What Products and Services Does PPII Offer?
- Formulates and manufactures nutraceutical supplements.
- Produces skin and hair care products.
- Offers energy drinks and skin rejuvenating serums.
- Develops fat management and skin treatment solutions.
- Creates products for fatty acid and cholesterol metabolism.
- Provides nutritional formulas for bone, joint, and connective tissue support.
- Offers sports-specific, women's, and men's formulas.
- Provides wellness, energy, and body sculpting products.
How Does PPII Make Money?
- Develops and manufactures a range of nutraceutical supplements and personal care products.
- Sells products through various distribution channels, including online retail and partnerships.
- Generates revenue through direct sales to consumers and wholesale distribution.
- Focuses on product innovation and marketing to drive sales and market share.
What Industry Does PPII Operate In?
Coenzyme-A Inc. operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and evolving consumer preferences. The global nutraceuticals market is experiencing substantial growth, driven by increasing health awareness and an aging population. Key trends include the rising demand for personalized nutrition and the growing popularity of natural and organic products. Coenzyme-A Inc. competes with established players and emerging brands, requiring continuous innovation and effective marketing strategies to maintain its market position.
Who Are PPII's Key Customers?
- Individuals seeking general health and wellness supplements.
- Consumers looking for skin and hair care solutions.
- Athletes and fitness enthusiasts seeking sports-specific formulas.
- Individuals with specific health concerns, such as joint pain or metabolic issues.
- Retailers and distributors of nutraceutical and personal care products.
Company Profile
Coenzyme-A Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Lynnwood, US. The company is led by CEO Nickoloaus D. Skouras. PPII has traded publicly since 2009.
Key Financial Metrics
Return on equity for Coenzyme-A Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. PPII trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.16 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
PPII Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has turned increasingly positive, with discussions highlighting the company's innovative approach to product development.
- Market perception has shifted favorably, as analysts recognize the company's growth strategy and its alignment with industry trends.
- Increased engagement from retail investors reflects a growing interest in Coenzyme-A's unique offerings, which could drive future demand.
Bear Case
- Concerns over market competition have been raised, with some investors wary of how Coenzyme-A will maintain its edge in a crowded space.
- Recent negative sentiment on social platforms indicates skepticism about the company's ability to scale operations effectively.
- There are lingering doubts about supply chain stability, which could impact production and delivery timelines.
- Some community members express caution, citing the company's past performance and questioning whether current enthusiasm is sustainable.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PPII Latest News
No recent news available for PPII.
PPII Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PPII.
Price Targets
Wall Street price target analysis for PPII.
PPII MoonshotScore
What does this score mean?
The MoonshotScore rates PPII 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Nickoloaus D. Skouras
CEO
Nickoloaus D. Skouras is the CEO of Coenzyme-A Inc. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Further research would be needed to provide a comprehensive background on Mr. Skouras's professional experience and credentials. His leadership is pivotal in guiding the company's strategic direction and operational execution.
Track Record: Information regarding Nickoloaus D. Skouras's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. Further research would be needed to assess his track record and contributions to Coenzyme-A Inc.'s performance and growth.
PPII OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Coenzyme-A Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to adhere to the same stringent reporting standards as those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited Disclosure: Lack of financial transparency and reporting requirements.
- Low Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Price Volatility: Significant price swings due to limited trading activity.
- Potential for Fraud: Higher risk of fraudulent activities and manipulation.
- Regulatory Scrutiny: Increased regulatory scrutiny and potential for delisting.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with OTC trading.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal disputes.
- Consistent revenue generation from core business activities.
- Clear and transparent communication with investors.
- Independent audits of financial statements (if available).
- Experienced management team with relevant industry expertise.
- Positive customer reviews and testimonials.
PPII Healthcare Stock FAQ
What does Coenzyme-A Inc. do?
Coenzyme-A Inc. formulates, manufactures, and markets a range of nutraceutical supplements, skin, and hair care products. The company operates both domestically and internationally, offering products such as energy drinks, skin rejuvenating serums, and specialized nutritional formulas. These products cater to diverse consumer needs, including general health and wellness, sports nutrition, and specific health concerns. Coenzyme-A Inc. aims to provide comprehensive solutions in the health and personal care markets.
What are the main risks for PPII?
The main risks for Coenzyme-A Inc. include intense competition in the nutraceutical and personal care markets, changing consumer preferences, and regulatory compliance requirements. As an OTC-listed company, PPII faces additional risks related to limited liquidity, disclosure, and potential for price volatility. Economic downturns could also affect consumer spending on discretionary products, impacting the company's revenue. Investors should carefully consider these risks before investing in PPII.
What are the key factors to evaluate for PPII?
Evaluate PPII on fundamentals, analyst consensus, and risk factors. Coenzyme-A Inc. presents a focused approach to the nutraceutical and personal care market, with a diverse product range and international presence. Not financial advice.
How frequently does PPII data refresh on this page?
PPII's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PPII's recent stock price performance?
Coenzyme-A Inc. (PPII) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio in nutraceuticals and personal care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PPII overvalued or undervalued right now?
Coenzyme-A Inc. (PPII) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PPII before investing?
Before investing in Coenzyme-A Inc. (PPII), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PPII to a portfolio?
Key strength of Coenzyme-A Inc. (PPII): Diverse product portfolio in nutraceuticals and personal care. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing.
- AI analysis is pending for PPII.